- Find a clinical trial
- MK-1084-007 / KANDLELIT-007
Non-small cell lung cancer (NSCLC)
MK-1084-007 / KANDLELIT-007
MK1084 in combination with Subcutaneous Pembrolizumab with berahyaluronidase alfa (MK3475A) versus Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC
Trial overview
Medical Oncology
Non-small cell lung cancer (NSCLC)
Lung & bronchus
III
Registration number: NCT07190248
Campbelltown
38 Camden Road, Campbelltown, NSW, 2560, Australia
Medical Oncologist
Dr Jessica Smith
B Sci (Hons) MBBS (Hons) MMed, FRACP
Thank you for submitting.
Thank you for submitting.
We will be in touch within 24 hours
Form submission error
An unexpected error has occurred.
You will need to complete the form again, sorry for the inconvenience.
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.